Literature DB >> 24624407

Equity in statin use in New Zealand.

Pauline Norris1, Simon Horsburgh2, Gordon Becket3, Shirley Keown4, Bruce Arroll5, Kirsten Lovelock2, Peter Crampton6, Jackie Cumming7, Peter Herbison2.   

Abstract

INTRODUCTION: Preventive medications such as statins are used to reduce cardiovascular risk. There is some evidence to suggest that people of lower socioeconomic position are less likely to be prescribed statins. In New Zealand, Maori have higher rates of cardiovascular disease. AIM: This study aimed to investigate statin utilisation by socioeconomic position and ethnicity in a region of New Zealand.
METHODS: This was a cross-sectional study in which data were collected on all prescriptions dispensed from all pharmacies in one city during 2005/6. Linkage with national datasets provided information on patients' age, gender and ethnicity. Socioeconomic position was identified using the New Zealand Index of Socioeconomic Deprivation 2006.
RESULTS: Statin use increased with age until around 75 years. Below age 65 years, those in the most deprived socioeconomic areas were most likely to receive statins. In the 55-64 age group, 22.3% of the most deprived population received a statin prescription (compared with 17.5% of the mid and 18.6% of the least deprived group). At ages up to 75 years, use was higher amongst Maori than non-Maori, particularly in middle age, where Maori have a higher risk of cardiovascular disease. In the 45-54 age group, 11.6% of Maori received a statin prescription, compared with 8.7% of non-Maori. DISCUSSION: Statin use approximately matched the pattern of need, in contrast to other studies which found under-treatment of people of low socioeconomic position. A PHARMAC campaign to increase statin use may have increased use in high-risk groups in New Zealand.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24624407

Source DB:  PubMed          Journal:  J Prim Health Care        ISSN: 1172-6156


  6 in total

Review 1.  Ethnic Variations in the Quality Use of Medicines in Older Adults: Māori and Non-Māori in Aotearoa New Zealand.

Authors:  Joanna Hikaka; Rhys Jones; Carmel Hughes; Martin J Connolly; Nataly Martini
Journal:  Drugs Aging       Date:  2021-01-12       Impact factor: 3.923

2.  Changing ethnic inequalities in mortality in New Zealand over 30 years: linked cohort studies with 68.9 million person-years of follow-up.

Authors:  George Disney; Andrea Teng; June Atkinson; Nick Wilson; Tony Blakely
Journal:  Popul Health Metr       Date:  2017-04-26

3.  Cross-sectional analysis of the prevalence and predictors of statin utilisation in Ireland with a focus on primary prevention of cardiovascular disease.

Authors:  Paula Byrne; John Cullinan; Catríona Murphy; Susan M Smith
Journal:  BMJ Open       Date:  2018-02-08       Impact factor: 2.692

4.  Statin Prescription Patterns and Associated Factors Among Patients with Type 2 Diabetes Mellitus Attending Diabetic Clinic at Muhimbili National Hospital, Dar es Salaam, Tanzania.

Authors:  Aneth Telesphore Bideberi; Reuben Mutagaywa
Journal:  Diabetes Metab Syndr Obes       Date:  2022-02-27       Impact factor: 3.168

5.  Relationship between Statin Utilization and Socioeconomic Deprivation in Hungary.

Authors:  Klára Boruzs; Attila Juhász; Csilla Nagy; Róza Ádány; Klára Bíró
Journal:  Front Pharmacol       Date:  2016-03-24       Impact factor: 5.810

6.  Preventive Pharmacotherapy for Cardiovascular Disease: A Modelling Study Considering Health Gain, Costs, and Cost-Effectiveness when Stratifying by Absolute Risk.

Authors:  Nhung Nghiem; Josh Knight; Anja Mizdrak; Tony Blakely; Nick Wilson
Journal:  Sci Rep       Date:  2019-12-20       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.